

**Summary of Consolidated Financial Results [ IFRS ]  
for the Fiscal Year Ended March 31, 2025**

May 14, 2025

Listed company name	: Sysmex Corporation
Code	: 6869
Listed stock exchanges	: Tokyo Stock Exchange
URL	: <a href="http://www.sysmex.co.jp/en">www.sysmex.co.jp/en</a>
Company representative	: Kaoru Asano, President
Contact	: Takuro Minami, Executive Vice President of Corporate Business Administration
Phone	: 078(265)-0500
Scheduled date for shareholders' meeting	: June 27, 2025
Scheduled date for dividend payment	: June 30, 2025
Scheduled date for filing of financial report	: June 26, 2025
Preparation of supplementary material for earnings	: Yes
Holding of earnings announcement	: Yes

(Unit: Millions of Yen)

**1. Results for the Fiscal Year Ended March 31, 2025**

(1) Operating results

(% changes as compared with the previous fiscal year)

	Net Sales		Operating profit		Profit before tax		Profit	
Year ended Mar. 31, 2025	508,643	10.2%	87,583	11.7%	79,221	6.2%	53,576	7.6%
Year ended Mar. 31, 2024	461,510	12.4%	78,382	6.4%	74,600	8.6%	49,774	8.9%

	Profit attributable to owners of the parent		Total comprehensive income		Basic earnings per share (Yen)	Diluted earnings per share (Yen)
Year ended Mar. 31, 2025	53,669	8.1%	49,434	(32.6)%	86.07	86.05
Year ended Mar. 31, 2024	49,639	8.4%	73,397	32.1%	79.27	79.24

	Return on equity (%)	Profit before tax to total assets (%)	Operating profit to net sales (%)
Year ended Mar. 31, 2025	12.0	12.3	17.2
Year ended Mar. 31, 2024	12.1	13.0	17.0

Reference:

Share of loss on equity method: 2,071 million yen for the year ended March 31, 2025; 2,849 million yen for the year ended March 31, 2024.

Note:

The Company conducted a three-for-one stock split on common stock with an effective date of April 1, 2024. Basic earnings per share and diluted earnings per share have been calculated as if the stock split had taken place at the beginning of the previous consolidated fiscal year.

(2) Financial condition

	Total assets	Total equity	Equity attributable to owners of the parent	Equity attributable to owners of the parent to total assets (%)	Equity attributable to owners of the parent per share (Yen)
As of Mar. 31, 2025	665,268	464,534	463,776	69.7	743.71
As of Mar. 31, 2024	618,920	432,897	432,045	69.8	692.94

Note:

The Company conducted a three-for-one stock split on common stock with an effective date of April 1, 2024. Equity attributable to owners of the parent per share have been calculated as if the stock split had taken place at the beginning of the previous consolidated fiscal year.

### (3) Cash flows

	Cash flows from operating activities	Cash flows from investing activities	Cash flows from financing activities	Cash and cash equivalents at the end of the term
Year ended Mar. 31, 2025	88,246	(52,488)	(24,322)	89,570
Year ended Mar. 31, 2024	63,905	(54,970)	(9,013)	75,507

## 2. Dividend

	Dividend per share					Total dividend payment (Millions of yen)	Dividend payout ratio (Consolidated) (%)	Dividend to equity attributable to owners of the parent (Consolidated) (%)
	First quarter	Second quarter	Third quarter	Year-end	Annual			
	(Yen)	(Yen)	(Yen)	(Yen)	(Yen)			
Year ended Mar. 31, 2024	—	42.00	—	42.00	84.00	17,583	35.4	6.6
Year ended Mar. 31, 2025	—	15.00	—	17.00	32.00	20,098	37.4	4.5
Year ending Mar. 31, 2026 (Forecast)	—	19.00	—	19.00	38.00		41.9	

Notes:

- The total amount of cash dividends for the fiscal year ending March 31, 2024 includes 63 million yen of the dividends for the shares of the Company held by the ESOP Trust. The total amount of cash dividends for the fiscal year ending March 31, 2025 includes 144 million yen of the dividends for the shares of the Company held by the ESOP Trust.
- The Company conducted a three-for-one stock split on common stock with an effective date of April 1, 2024. However, actual dividend amounts prior to this stock split are shown for the fiscal years ended March 31, 2024.
- Composition of the year-end dividend for the fiscal year ended March 31, 2026:  
Second quarter: Ordinary dividend 18.00 yen per share and Commemorative dividend of 30 years anniversary of listing 1.00 yen per share. Year-end: Ordinary dividend 18.00 yen per share and Commemorative dividend of 30 years anniversary of listing 1.00 yen per share.

## 3. Financial Forecast for the Year Ending March 31, 2026

(% changes as compared with the corresponding period of the previous fiscal year)

	Net Sales		Operating profit		Profit before tax		Profit attributable to owners of the parent		Basic earnings per share (Yen)
Six months ending Sep. 30, 2025	252,500	4.1%	44,500	(0.0)%	42,000	9.7%	28,000	7.7%	44.90
Year ending Mar. 31, 2026	535,000	5.2%	91,500	4.5%	85,500	7.9%	57,000	6.2%	91.40

## 4. Other Information

- Significant changes in scope of consolidation: No
- Changes in accounting policies and accounting estimates
  - Changes in accounting policies required by IFRS: No
  - Other changes in accounting policies: No
  - Changes in accounting estimates: No
- Number of outstanding stock (common stock)
  - Number of outstanding stock at the end of each fiscal period (including treasury stock):  
629,473,176 shares as of Mar. 31, 2025; 629,371,116 shares as of Mar. 31, 2024
  - Number of treasury stock at the end of each fiscal period:  
5,873,371 shares as of Mar. 31, 2025; 5,872,332 shares as of Mar. 31, 2024
  - Average number of outstanding stock for each period (cumulative):  
623,531,760 shares for the year ended Mar. 31, 2025  
626,187,289 shares for the year ended Mar. 31, 2024

Notes:

1. The Company has introduced Stock-Granting Employee Stock Ownership Plan (ESOP) Trust. Company shares held by the trust are included in treasury stock and are excluded from calculations of the number of treasury stock at the end of the fiscal period and the average number of outstanding stock for the period.
2. The Company conducted a three-for-one stock split on common stock with an effective date of April 1, 2024. The number of outstanding stock at the end of the fiscal period, the number of treasury stock at the end of the fiscal period, and the average number of outstanding stock for the period are calculated as if the stock split had taken place at the beginning of the previous consolidated fiscal year.

**(Reference) Summary of the Non-consolidated Financial Results for the Year Ended March 31, 2025**

(1) Non-consolidated operating results

(% changes as compared with the previous fiscal year)

	Net Sales		Operating income		Ordinary income		Net income	
Year ended Mar. 31, 2025	236,780	7.0%	56,289	8.9%	65,598	(0.6)%	25,219	(26.5)%
Year ended Mar. 31, 2024	221,231	8.1%	51,703	3.2%	65,968	14.2%	34,298	(20.0)%

	Net income per share (Yen)	Diluted net income per share (Yen)
Year ended Mar. 31, 2025	40.45	40.43
Year ended Mar. 31, 2024	54.77	54.75

Note:

The Company conducted a three-for-one stock split on common stock with an effective date of April 1, 2024. Net income per share and diluted net income per share are calculated as if the stock split had taken place at the beginning of the previous consolidated fiscal year.

(2) Non-consolidated financial condition

	Total assets	Net assets	Equity ratio (%)	Net assets per share (Yen)
As of Mar. 31, 2025	364,655	275,148	75.2	439.55
As of Mar. 31, 2024	355,431	267,897	75.1	427.87

Reference:

Equity capital: 274,105 million yen as of March 31, 2025; 266,778 million yen as of March 31, 2024.

Note:

The Company conducted a three-for-one stock split on common stock with an effective date of April 1, 2024. Net assets per share are calculated as if the stock split had taken place at the beginning of the previous consolidated fiscal year.

Note: Summaries of financial results are not subject to audit by certified public accountants or auditing firm.

\* Explanation regarding the appropriate use of financial forecast and other information

1. The forecasts and future projections contained herein have been prepared on the basis of rational decisions given the information available as of the date of announcement of this document. These forecasts do not represent a commitment by the Company, and actual performance may differ substantially from forecasts for a variety of reasons. Please refer to “4) Outlook for future” within “1. Overview of operating performance” on page 4 of the attachment to this document.
2. Supplementary financial materials (in Japanese and English) will be posted on the Sysmex website on Wednesday, May 14, 2025.

## **Content of Supplementary Materials**

1. Overview of operating performance	2
1) Operating performance during the year	2
2) Financial conditions at end of the year	3
3) Cash flows during the year	3
4) Outlook for future	4
2. Basic perspective on selection of accounting standards	4
3. Consolidated financial statements and notes	5
1) Consolidated statement of financial position	5
2) Consolidated statement of income	7
3) Consolidated statement of comprehensive income	8
4) Consolidated statement of changes in equity	9
5) Consolidated statement of cash flows	11
6) Notes to the consolidated financial statements	12
1. Notes related to the going concern assumption	12
2. Segment information	12
3. Per-share information	15
4. Significant subsequent event	15

# 1. Overview of operating performance

## 1) Operating performance during the year

Future-related information contained in the text below is based on the judgement as of the end of the fiscal period under review.

During the fiscal year ended March 31, 2025, although the global economy remained generally stable, some countries continued to experience elevated inflation. In addition, newly implemented tariff policies in the United States sharply increased economic policy uncertainty, particularly in the areas of trade and public finance. Against this backdrop, while personal consumption and capital investment remained firm in the United States, economic growth was constrained in Europe due to weakness in manufacturing and goods exports. In China, domestic demand remained sluggish. Furthermore, geopolitical risks related to the Middle East and the Russia–Ukraine situation continued, and the outlook for the global economy remained uncertain. In Japan, although GDP shrank slightly due to temporary supply disruptions, domestic demand provided support, and the economy followed a modest recovery trajectory.

In the healthcare field, economic growth in emerging markets and the aging of populations worldwide have continued to drive up demand for healthcare. At the same time, the need for improved quality of care and healthcare services is increasing. As medical functions become more decentralized, the importance of prevention, early diagnosis, and self-medication is rising. Meanwhile, disparities in healthcare and issues related to access are expected to persist going forward. Furthermore, we anticipate advancements in technological innovation such as gene analysis, ultrahigh sensitive measurement, and miniaturization, which will be applied to healthcare. Demand for personalized medicine will grow, and we expect the practical application of new treatment methods such as regenerative and cellular medicine and genomic medicine. Additionally, digital transformation (DX) in the healthcare sector is accelerating, spurred by the proliferation of artificial intelligence (AI), and the implementation and expanded applications of robotic technologies are also progressing. These trends are expected to provide further growth opportunities.

Under these circumstances, sales increased across all regions and in all fields. As a result, consolidated net sales exceeded ¥500 billion, and we achieved record highs in net sales, operating profit, and profit attributable to owners of the parent. Going forward, we aim for further growth by accelerating business development in the field of surgical robot systems and in emerging markets, including in India, where we have established our first site with production capabilities for both reagents and instruments.

### Net sales by destination

		Year ended March 31, 2024		Year ended March 31, 2025		YoY (Previous period = 100)
		Amount (Millions of yen)	Percentage of total (%)	Amount (Millions of yen)	Percentage of total (%)	
Japan		62,184	13.5	67,786	13.3	109.0
	Americas	118,782	25.7	131,148	25.8	110.4
	EMEA (Europe, the Middle East, and Africa)	125,349	27.2	140,398	27.6	112.0
	China	109,952	23.9	117,970	23.2	107.3
	Asia Pacific	45,241	9.8	51,339	10.1	113.5
Overseas subtotal		399,325	86.5	440,857	86.7	110.4
Total		461,510	100.0	508,643	100.0	110.2

In Japan, sales of instruments and reagents in the hematology field and reagents in the hemostasis field increased. As a result, sales in Japan rose 9.0% year on year, to ¥67,786 million. The domestic sales ratio fell 0.2 percentage point, to 13.3%.

Overseas, sales of reagents and maintenance services in the hematology field increased, as did sales of hemostasis reagents. In addition, the yen depreciated. Consequently, overseas sales grew 10.4% year on year, to ¥440,857 million, and the overseas sales ratio rose 0.2 percentage point, to 86.7%.

Selling, general and administrative (SG&A) expenses climbed 12.7% year on year, to ¥150,848 million, mainly due to an increase in personnel and promotional activities associated with the expansion of business scale. Research and development (R&D) expenses edged up 0.2% year on year, to ¥31,455 million.

As a result, for the fiscal year ended March 31, 2025, the Group recorded consolidated net sales of ¥508,643 million (up 10.2% year on year), operating profit of ¥87,583 million (up 11.7%), profit before tax of ¥79,221

million (up 6.2%), and profit attributable to owners of the parent of ¥53,669 million (up 8.1%).

#### Performance by segment

##### (1) Headquarters

In Japan, greater demand led to higher sales of instruments and reagents in the hematology and hemostasis fields. As a result, segment sales rose 9.7% year on year, to ¥93,988 million.

On the profit front, SG&A expenses rose, but higher sales and an improved cost of sales ratio pushed up segment profit (operating profit) 8.8%, to ¥59,104 million.

##### (2) Americas RHQ

In North America, sales of hematology and urinalysis reagents and maintenance services rose. In Central and South America, centered on the Brazilian market, sales of hematology instruments and reagents grew, and sales of urinalysis reagents increased. As a result, overall sales in the Americas grew 9.7% year on year, to ¥122,916 million.

On the profit front, although sales increased, we also saw SG&A expenses rise as we boosted headcount in line with an increase and scale, causing segment profit (operating profit) to drop 8.9% year on year, to ¥6,743 million.

##### (3) EMEA (Europe, the Middle East, and Africa) RHQ

Benefiting from the effect of the expansion of direct sales in Saudi Arabia, sales of hematology instruments and reagents grew, as did sales of hemostasis reagents. Accordingly, sales were ¥135,671 million, up 11.6% year on year.

Profit was affected by higher SG&A expenses, stemming from the impact of inflation, but higher sales and the improvement in the cost of sales ratio led to a 2.5% year on year increase in segment profit (operating profit), to ¥10,583 million.

##### (4) China RHQ

Sales of hematology and hemostasis reagents increased, buoyed by a rise in the number of tests. Consequently, sales rose 7.3%, to ¥117,828 million.

Segment profit (operating profit) surged 35.6% year on year, to ¥10,646 million, owing to higher sales, the improvement in the cost of sales ratio and lower SG&A expenses.

##### (5) Asia Pacific (Asia Pacific) RHQ

In the Asia Pacific region, growth in the Indian market contributed to higher sales of instruments and reagents in the hematology field, as well as reagents in the hemostasis field. As a result, segment sales rose 17.6% year on year, to ¥38,239 million.

Looking at profit, higher sales, and the improvement in the cost of sales ratio resulted in a 50.7% increase in segment profit (operating profit), reaching ¥3,579 million.

#### 2) Financial conditions at end of the year

As of March 31, 2025, total assets amounted to ¥665,268 million, an increase of ¥46,348 million from the previous fiscal year-end. Major factors included a ¥14,062 million increase in cash and cash equivalents, a ¥13,517 million rise in property, plant and equipment, a ¥5,940 million increase in trade and other receivables (current assets) and a ¥5,543 million increase in trade and other receivables (non-current assets).

Total liabilities came to ¥200,734 million, up ¥14,711 million from the previous fiscal year-end. Key contributors included increases of ¥5,046 million in non-current lease liabilities, ¥3,759 million in long-term loans payable, and ¥2,098 million in accrued bonuses.

Total equity came to ¥464,534 million, up ¥31,637 million from March 31, 2024. Among principal factors, retained earnings increased ¥36,835 million, while other components of equity decreased ¥5,388 million. Equity attributable to owners of the parent to total assets amounted to 69.7% on March 31, 2025, down 0.1 percentage points from 69.8% on March 31, 2024.

#### 3) Cash flows during the year

As of March 31, 2025, cash and cash equivalents amounted to ¥89,570 million, up ¥14,062 million from March 31, 2024.

Cash flows from various activities during the fiscal year are described in more detail below.

##### (Cash flows from operating activities)

Net cash provided by operating activities was ¥88,246 million, up ¥24,340 million from the previous fiscal year. As principal factors, profit before tax provided ¥79,221 million (¥4,620 million more than in the preceding year), depreciation and amortization provided ¥39,033 million (up ¥3,144 million) and income taxes paid used ¥27,723 million (down ¥1,250 million).

##### (Cash flows from investing activities)

Net cash used in investing activities was ¥52,488 million (down ¥2,481 million). Among major factors, purchases of property, plant and equipment used ¥29,226 million (up ¥3,616 million), purchases of intangible assets used ¥20,733 million (down ¥3,847 million).

(Cash flows from financing activities)

Net cash used in financing activities was ¥24,322 million (up ¥15,308 million). This was mainly due to proceeds from long-term loans payable of ¥4,700 million (down ¥24,300 million), dividends paid of ¥18,081 million (up ¥502 million), and repayments of lease liabilities of ¥10,561 million (up ¥1,492 million).

#### 4) Outlook for future

Looking ahead, we expect the global economy to continue its stable growth trajectory, albeit without strong momentum, fueled by a recovery in real incomes due to a decline in the inflation rate. However, the foundations for growth and associated risks differ by country. In Japan, growth is expected to be steady, supported by rising personal consumption and corporate capital investment. In the United States, easing of monetary tightening and a favorable financial environment are expected to sustain economic growth through robust personal consumption and active investment, although we expect the growth rate to decelerate gradually. In Europe, we believe growth will accelerate. However, risks remain, including continued weakness in the manufacturing sector—particularly in Germany—and geopolitical tensions. In China, prolonged stagnation in the real estate market and the impact of tariffs on U.S.-bound exports present risks. Furthermore, geopolitical risks associated with the Middle East and the Russia–Ukraine situation, along with global trade friction centered on the United States, continue to cast a shadow over the outlook for the world economy.

Looking at the healthcare environment, demand for higher healthcare quality and services is growing. Furthermore, artificial intelligence (AI), information communication technology (ICT) and other leading-edge technologies are rapidly being applied to the healthcare field. Rising healthcare demand in emerging markets, spurred by economic growth, is expected to sustain future growth. The global COVID-19 pandemic has also prompted considerations about healthcare systems and the potential for major changes in the healthcare environment itself. We anticipate further opportunities for growth, owing to increasingly diverse medical functions, improved access to healthcare, and the creation of new value in the area of self-medication.

Under these circumstances, in April 2023 the Sysmex Group commenced a new mid-term management plan (for the fiscal years ending March 31, 2024 to 2026). By promoting key actions during this period, we aim to achieve sustainable growth and strengthen the management foundation to support it.

Our consolidated operating forecast for the fiscal year ending March 31, 2026 calls for increased sales and profits as we expand our product lineup and reinforce our sales and service structure. We forecast net sales of ¥535,000 million, operating profit of ¥91,500 million, profit before tax of ¥85,500 million and profit attributable to owners of the parent of ¥57,000 million.

Note: Our assumptions for annual average exchange rates are US\$1=¥142.0 and €1=¥160.0

The forecast outlined above is based on currently available information. Actual performance may differ from this forecast for a variety of reasons.

## 2. Basic perspective on selection of accounting standards

The Sysmex Group voluntarily adopted IFRS from the fiscal year ended March 31, 2017. Our aim is to increase convenience to shareholders and investors in Japan and overseas by enhancing the international comparability of our financial information in capital markets.

### 3. Consolidated financial statements and notes

#### 1) Consolidated statement of financial position

(Unit: Millions of yen)

	As of March 31, 2024	As of March 31, 2025
Assets		
Current assets		
Cash and cash equivalents	75,507	89,570
Trade and other receivables	157,067	163,007
Inventories	79,123	81,811
Other short-term financial assets	1,310	654
Income taxes receivable	934	1,246
Other current assets	29,515	28,531
Total current assets	343,459	364,821
Non-current assets		
Property, plant and equipment	116,693	130,211
Goodwill	17,221	14,205
Intangible assets	86,786	92,146
Investments accounted for using the equity method	472	339
Trade and other receivables	21,435	26,978
Other long-term financial assets	14,034	12,034
Asset for retirement benefits	458	0
Other non-current assets	4,339	6,880
Deferred tax assets	14,018	17,651
Total non-current assets	275,461	300,447
Total assets	618,920	665,268



(Unit: Millions of yen)

	As of March 31, 2024	As of March 31, 2025
Liabilities and equity		
Liabilities		
Current liabilities		
Trade and other payables	33,602	31,865
Lease liabilities	8,659	9,250
Other current financial liabilities	1,028	1,403
Income taxes payable	12,476	12,784
Provisions	1,159	1,164
Contract liabilities	16,591	18,098
Accrued expenses	21,643	22,355
Accrued bonuses	12,611	14,709
Other current liabilities	10,311	11,194
Total current liabilities	118,084	122,826
Non-current liabilities		
Long-term loans payable	28,600	32,359
Lease liabilities	18,080	23,126
Other non-current financial liabilities	76	56
Liability for retirement benefits	2,239	2,127
Provisions	674	1,054
Other non-current liabilities	10,350	11,608
Deferred tax liabilities	7,917	7,575
Total non-current liabilities	67,938	77,908
Total liabilities	186,023	200,734
Equity		
Equity attributable to owners of the parent		
Capital stock	14,729	14,887
Capital surplus	20,830	20,960
Retained earnings	365,985	402,820
Treasury stock	(12,315)	(12,318)
Other components of equity	42,814	37,425
Total equity attributable to owners of the parent	432,045	463,776
Non-controlling interests	851	758
Total equity	432,897	464,534
Total liabilities and equity	618,920	665,268

## 2) Consolidated statement of income

(Unit: Millions of yen)

	Year ended March 31, 2024	Year ended March 31, 2025
Net sales	461,510	508,643
Cost of sales	219,013	236,665
Gross profit	242,497	271,977
Selling, general and administrative expenses	133,798	150,848
Research and development expenses	31,402	31,455
Impairment loss	2,210	3,211
Other operating income	4,203	2,070
Other operating expenses	905	948
Operating profit	78,382	87,583
Financial income	937	1,078
Financial expenses	2,386	3,518
Share of profit (loss) of associates accounted for using the equity method	(2,849)	(2,071)
Foreign exchange gain (loss)	516	(3,850)
Profit before tax	74,600	79,221
Income taxes expenses	24,826	25,645
Profit	49,774	53,576
Profit attributable to		
Owners of the parent	49,639	53,669
Non-controlling interests	135	(93)
Profit	49,774	53,576
(Unit: Yen)		
Earnings per share		
Basic	79.27	86.07
Diluted	79.24	86.05

## 3) Consolidated statement of comprehensive income

(Unit: Millions of yen)

	Year ended March 31, 2024	Year ended March 31, 2025
Profit	49,774	53,576
Other comprehensive income		
Items that will not be reclassified subsequently to profit or loss		
Net gain (loss) on financial assets measured at fair value through other comprehensive income	250	(2,194)
Remeasurements of defined benefit liabilities	(181)	(114)
Total	69	(2,308)
Items that may be reclassified subsequently to profit or loss		
Exchange differences on translation of foreign operations	23,526	(1,830)
Share of other comprehensive income of investments accounted for using the equity method	27	(3)
Total	23,553	(1,833)
Total other comprehensive income	23,623	(4,141)
Comprehensive income	73,397	49,434
Comprehensive income attributable to		
Owners of the parent	73,262	49,527
Non-controlling interests	135	(93)
Comprehensive income	73,397	49,434

4) Consolidated statement of changes in equity  
For the year ended March 31, 2024

(Unit: Millions of yen)

	Equity attributable to owners of the parent						Non-controlling interests	Total equity
	Capital stock	Capital surplus	Retained earnings	Treasury stock	Other components of equity	Total		
As of April 1, 2023	14,282	20,580	334,192	(314)	18,925	387,665	690	388,356
Profit	—	—	49,639	—	—	49,639	135	49,774
Other comprehensive income	—	—	—	—	23,623	23,623	0	23,623
Comprehensive income	—	—	49,639	—	23,623	73,262	135	73,397
Exercise of warrants	447	255	—	—	—	703	—	703
Share-based payment transactions	—	—	—	—	—	—	—	—
Cash dividends	—	—	(17,579)	—	—	(17,579)	—	(17,579)
Purchase of treasury stock	—	—	—	(12,001)	—	(12,001)	—	(12,001)
Disposal of treasury stock	—	—	—	—	—	—	—	—
Transfer to retained earnings	—	—	(266)	—	266	—	—	—
Changes from business combination	—	—	—	—	—	—	87	87
Changes due to acquisition of control of a subsidiary	—	(5)	—	—	—	(5)	(62)	(67)
Changes due to loss of control of a subsidiary	—	—	—	—	—	—	(0)	(0)
Total transactions with the owners	447	250	(17,845)	(12,001)	266	(28,882)	25	(28,857)
As of March 31, 2024	14,729	20,830	365,985	(12,315)	42,814	432,045	851	432,897

For the year ended March 31, 2025

(Unit: Millions of yen)

	Equity attributable to owners of the parent						Non-controlling interests	Total equity
	Capital stock	Capital surplus	Retained earnings	Treasury stock	Other components of equity	Total		
As of April 1, 2024	14,729	20,830	365,985	(12,315)	42,814	432,045	851	432,897
Profit	—	—	53,669	—	—	53,669	(93)	53,576
Other comprehensive income	—	—	—	—	(4,141)	(4,141)	—	(4,141)
Comprehensive income	—	—	53,669	—	(4,141)	49,527	(93)	49,434
Exercise of warrants	158	90	—	—	—	248	—	248
Share-based payment transactions	—	39	—	—	—	39	—	39
Cash dividends	—	—	(18,081)	—	—	(18,081)	—	(18,081)
Purchase of treasury stock	—	—	—	(2)	—	(2)	—	(2)
Disposal of treasury stock	—	0	—	0	—	0	—	0
Transfer to retained earnings	—	—	1,247	—	(1,247)	—	—	—
Changes from business combination	—	—	—	—	—	—	—	—
Changes due to acquisition of control of a subsidiary	—	—	—	—	—	—	—	—
Changes due to loss of control of a subsidiary	—	—	—	—	—	—	—	—
Total transactions with the owners	158	129	(16,834)	(2)	(1,247)	(17,796)	—	(17,796)
As of March 31, 2025	14,887	20,960	402,820	(12,318)	37,425	463,776	758	464,534

## 5) Consolidated statement of cash flows

(Unit: Millions of yen)

	Year ended March 31, 2024	Year ended March 31, 2025
Cash flows from operating activities		
Profit before tax	74,600	79,221
Depreciation and amortization	35,888	39,033
Impairment loss	2,210	3,211
Interest and dividends income	(863)	(899)
Interest expenses	1,571	1,949
Share of loss (profit) of associates accounted for using the equity method	2,849	2,071
Loss on retirement of non-current assets	381	383
Decrease (increase) in trade receivable	(21,987)	(7,150)
Decrease (increase) in advance payments	474	706
Decrease (increase) in inventories	(1,676)	(6,320)
Increase (decrease) in trade payable	1,274	162
Increase (decrease) in accounts payable—other	118	(520)
Increase (decrease) in contract liabilities	201	1,720
Increase (decrease) in accrued expenses	1,483	1,113
Decrease/increase in consumption taxes receivable/payable	1,157	(1,374)
Increase (decrease) in accrued bonuses	749	2,118
Other—net	(4,769)	1,743
Subtotal	93,665	117,168
Interest and dividend received	598	654
Interest paid	(1,383)	(1,853)
Income taxes paid	(28,974)	(27,723)
Net cash provided by (used in) operating activities	63,905	88,246
Cash flows from investing activities		
Purchases of property, plant and equipment	(25,610)	(29,226)
Proceeds from sales of property, plant and equipment	527	702
Purchases of intangible assets	(24,581)	(20,733)
Payments resulting in an increase in long-term prepaid expenses	(841)	(1,001)
Purchases of investments in equity instruments	(4,026)	(3,821)
Proceeds from the sale of equity instruments	—	1,853
Acquisitions of subsidiaries or other businesses	(574)	—
Payments into time deposits	(1,460)	(1,544)
Proceeds from withdrawal of time deposits	1,260	1,777
Other—net	337	(495)
Net cash provided by (used in) investing activities	(54,970)	(52,488)
Cash flows from financing activities		
Proceeds from long-term loans payable	29,000	4,700
Repayments of long-term loans payable	—	(626)
Exercise of warrants	703	248
Purchase of treasury shares	(12,001)	(2)
Dividends paid	(17,579)	(18,081)
Repayments of lease liabilities	(9,068)	(10,561)
Other—net	(67)	2
Net cash provided by (used in) financing activities	(9,013)	(24,322)
Effects of exchange rate changes on cash and cash equivalents	6,125	2,627
Net increase (decrease) in cash and cash equivalents	6,047	14,062
Cash and cash equivalents at the beginning of the term	69,460	75,507
Cash and cash equivalents at the end of the term	75,507	89,570

6) Notes to the consolidated financial statements

1. Notes related to the going concern assumption

Not applicable

2. Segment information

1) Overview of reportable segments

The reportable segments of the Company and its subsidiaries (the Group) are the constituent business units of the Group for which separate financial data are available and that are examined on a regular basis for the purpose of enabling the Managing Board to allocate managerial resources and evaluate results of operations.

The Group is primarily engaged in the manufacture and sale of diagnostic instruments and reagents. These businesses are conducted in Japan and East Asia by Sysmex and in the Americas, EMEA, China, and the Asia Pacific by regional headquarters established therein. These companies formulate comprehensive strategies tailored to regional characteristics and conduct business activities accordingly. Some overseas subsidiaries are managed by Sysmex depending on the nature of their business.

To date, we have organized reportable segments geographically. However, from the fiscal year ended March 31, 2025, we have integrated our performance management system to focus on managing company-specific segments in the interest of making performance management more efficient. We have revised the reportable segments based on this management approach. The five managing company-specific segments are “Headquarters,” “Americas RHQ,” “EMEA RHQ,” “China RHQ,” and “AP RHQ.”

The companies included in these reportable segments are outlined below.

Reportable segments	Companies included in the reportable segments
Headquarters	Sysmex Corporation, Sysmex RA Co., Ltd., 12 other domestic subsidiaries, Oxford Gene Technology IP Limited, Sysmex Partec GmbH, Sysmex Korea Co., Ltd., 12 other overseas subsidiaries
Americas RHQ	Sysmex America, Inc., Sysmex Reagents America, Inc., Sysmex do Brasil Industria e Comercio Ltda., five other subsidiaries in the Americas
EMEA RHQ	Sysmex Europe SE, Sysmex Deutschland GmbH, Sysmex UK Limited, Sysmex France S.A.S., 25 other subsidiaries in the EMEA region
China RHQ	Sysmex Shanghai Ltd., Jinan Sysmex Medical Electronics Co., Ltd., two other subsidiaries in China
AP RHQ	Sysmex Asia Pacific Pte Ltd., Sysmex India Pvt. Ltd., nine other subsidiaries in the Asia Pacific region

2) Segment profit and operating results

Profit and operating results from continuing operations by reportable segment of the Group are as follows:

Intersegment sales are determined based on market prices or costs of goods manufactured.

Accounting policies of reporting segments are consistent with the Group’s accounting policies indicated in the consolidated financial statements for the previous fiscal year

Segment information for the previous fiscal year is based on the revised reportable segment categories.

For the year ended March 31, 2024

(Unit: Millions of yen)

	Reportable segment						Adjustments (Note 1)	Consolidated (Note 2)
	Head- quarters	Americas RHQ	EMEA RHQ	China RHQ	AP RHQ	Total		
Sales								
Sales to external customers	85,642	111,997	121,568	109,797	32,503	461,510	—	461,510
Intersegment sales	152,958	35	992	478	52	154,517	(154,517)	—
Total	238,601	112,033	122,560	110,276	32,555	616,027	(154,517)	461,510
Segment profit	54,309	7,399	10,327	7,852	2,376	82,265	(3,882)	78,382
Financial income	—	—	—	—	—	—	—	937
Financial expenses	—	—	—	—	—	—	—	2,386
Share of profit (loss) on equity method	—	—	—	—	—	—	—	(2,849)
Foreign exchange gain (loss)	—	—	—	—	—	—	—	516
Profit before tax	—	—	—	—	—	—	—	74,600
Income tax expenses	—	—	—	—	—	—	—	24,826
Profit	—	—	—	—	—	—	—	49,774
Other								
Depreciation and amortization (Note 3)	21,392	5,354	5,027	1,146	3,790	36,711	(822)	35,888
Impairment loss	1,859	285	—	—	65	2,210	—	2,210

Notes:

1. Segment profit adjustments of negative ¥3,882 million include negative ¥3,294 million for the unrealized gains on inventories, and negative ¥587 million for the unrealized gains on non-current assets.
2. Segment profit is reconciled with operating profit in the consolidated statement of income.
3. The negative ¥822 million reconciliation in depreciation and amortization is an adjustment related to intersegment transactions.



For the year ended March 31, 2025

(Unit: Millions of yen)

	Reportable segment						Adjustments (Note 1)	Consolidated (Note 2)
	Head- quarters	Americas RHQ	EMEA RHQ	China RHQ	AP RHQ	Total		
Sales								
Sales to external customers	93,988	122,916	135,671	117,828	38,239	508,643	—	508,643
Intersegment sales	161,269	30	604	489	50	162,444	(162,444)	—
Total	255,258	122,946	136,276	118,317	38,289	671,088	(162,444)	508,643
Segment profit	59,104	6,743	10,583	10,646	3,579	90,657	(3,073)	87,583
Financial income	—	—	—	—	—	—	—	1,078
Financial expenses	—	—	—	—	—	—	—	3,518
Share of profit (loss) on equity method	—	—	—	—	—	—	—	(2,071)
Foreign exchange gain (loss)	—	—	—	—	—	—	—	(3,850)
Profit before tax	—	—	—	—	—	—	—	79,221
Income tax expenses	—	—	—	—	—	—	—	25,645
Profit	—	—	—	—	—	—	—	53,576
Other								
Depreciation and amortization (Note 3)	22,120	6,024	6,305	1,142	4,388	39,981	(948)	39,033
Impairment loss	3,207	—	—	—	3	3,211	—	3,211

Notes:

1. Segment profit adjustments of negative ¥3,073 million include negative ¥2,409 million for the unrealized gains on inventories, and negative ¥663 million for the unrealized gains on non-current assets.
2. Segment profit is reconciled with operating profit in the consolidated statement of income.
3. The negative ¥948 million reconciliation in depreciation and amortization is an adjustment related to intersegment transactions.

### 3. Per-share information

The basis for calculating basic profit per share and diluted profit per share is as follows.

	Year ended March 31, 2024	Year ended March 31, 2025
Basis for calculating basic earnings per share		
Profit attributable to owners of parent (Millions of yen)	49,639	53,669
Profit not attributable to common stock shareholders of the parent (Millions of yen)	—	—
Profit used in calculating basic earnings per share (Millions of yen)	49,639	53,669
Average number of common stock shares during the period (Thousands of shares)	626,187	623,531
Basis for calculating diluted earnings per share		
Profit used in calculating basic earnings per share (Millions of yen)	49,639	53,669
Profit adjustment (Millions of yen)	—	—
Profit used in calculating diluted earnings per share (Millions of yen)	49,639	53,669
Average number of common stock shares during the period (Thousands of shares)	626,187	623,531
Effect of dilutive shares (Thousands of shares)	238	194
Average number of common stock shares after adjustment for dilution (Thousands of shares)	626,425	623,726

Notes: 1. The Company has introduced Stock-Granting Employee Stock Ownership Plan (ESOP) Trust. Company shares held by the trust are included in treasury stock and are excluded from calculations of the Company's own shares and average number of shares during the period.

2. The Company conducted a three-for-one stock split on common stock with an effective date of April 1, 2024. The basic earnings per share, and the diluted earnings per share are calculated as if the stock split had taken place at the beginning of the previous fiscal year.

### 4. Significant subsequent event

(Introduction of a performance-linked stock-granting compensation plan for members of the Managing Board)

The Company resolved at a meeting of the Managing Board held on May 14, 2025, to introduce a new performance-linked stock-granting compensation plan (hereinafter, the "Plan") and to submit a proposal regarding the Plan for approval at the 58th Ordinary General Meeting of Shareholders scheduled for June 27, 2025 (hereinafter, the "General Meeting of Shareholders").

#### 1. Objective for Introducing the Plan

The Company has decided to revise its executive compensation system and newly introduce a stock-based compensation plan to clarify the link between the compensation of members of the Managing Board (excluding outside members of the Managing Board, members of the Managing Board who are Audit and Supervisory Committee members, and non-residents of Japan) and Executive Officers (excluding non-residents of Japan; hereinafter collectively referred to as the "Eligible Executives") and the Company's business performance and stock value. The aim is to heighten Eligible Executives' awareness of contributing to the enhancement of medium- to long-term performance and corporate value.

#### 2. Overview of the Plan

- (1) Implementation of the Plan is conditional upon receiving approval at the General Meeting of Shareholders for the relevant executive compensation resolution.
- (2) The Plan will adopt a mechanism known as an executive compensation BIP (Board Incentive Plan) trust. Under the Plan, the Company will grant to Eligible Executives shares of the Company and/or cash equivalent to the conversion value of such shares (hereinafter collectively referred to as the "Company's shares, etc.") based on factors such as position and degree of achievement of performance targets (hereinafter referred to as "delivery, etc.>").
- (3) Upon expiration of the trust period of the executive compensation BIP trust (hereinafter, the "Trust") established for the implementation of the Plan, the Company intends to either establish a new Trust or amend and provide additional trust funds to the existing Trust in order to continue implementing the Plan on an

ongoing basis.

Details of the Trust Agreement

1 Type of trust	Monetary trust other than a specified, individually managed monetary trust (benefit trust)
2 Purpose of trust	To provide incentives to Eligible Executives
3 Trustor	The Company
4 Trustee	Mitsubishi UFJ Trust and Banking Corporation (planned) (Co-trustee: The Master Trust Bank of Japan, Ltd. (planned))
5 Beneficiaries	Eligible Executives who meet the requirements for beneficiaries
6 Trust administrator	A third party independent from the Company (Certified Public Accountant)
7 Date of trust agreement	August 2025 (planned)
8 Trust period	August 2025 to August 2029 (planned)
9 Plan commencement date	August 2025 (planned)
10 Exercise of voting rights	Not to be exercised
11 Type of shares to be acquired	Common shares of the Company
12 Trust fund amount	¥880 million (planned) (including trust fees and expenses)
13 Share acquisition period	August 1, 2025 to August 30, 2025 (planned)
14 Method of share acquisition	Purchase from the stock market
15 Rights holder	The Company
16 Residual assets	Any residual assets the Company, as rights holder, may receive will be limited to the trust reserve, calculated by subtracting the funds used to acquire shares from the trust fund.